OncoMatch/Clinical Trials/NCT06904482
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Is NCT06904482 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Haplo-Identical / Cord Blood Transplant for agvhd.
Treatment: Haplo-Identical / Cord Blood Transplant — The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Allowed: FLT3 mutation
poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Allowed: KMT2A (MLL) 11q23 rearrangement
poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Allowed: TP53 mutation
poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG <2
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: allowed if >6 months prior
Prior autologous stem cell transplant or CAR-T within the preceding 6 months
Cannot have received: CAR-T cell therapy
Exception: allowed if >6 months prior
Prior autologous stem cell transplant or CAR-T within the preceding 6 months
Cannot have received: allogeneic transplant
prior allogeneic transplant
Lab requirements
Kidney function
Creatinine clearance < 40ml/min (Cockcroft-Gault)
Liver function
Bilirubin > 2X institutional upper limit of normal unless Gilbert syndrome; AST (SGOT) > 3X institutional upper limit of normal; ALT (SGPT) > 3X institutional upper limit of normal
Cardiac function
left ventricular ejection fraction < 40%
Creatinine clearance < 40ml/min (Cockcroft-Gault); Bilirubin > 2X institutional upper limit of normal unless Gilbert syndrome; AST (SGOT) > 3X institutional upper limit of normal; ALT (SGPT) > 3X institutional upper limit of normal; Pulmonary function: DLCOc < 60%; Cardiac: left ventricular ejection fraction < 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify